Pō a Ao Healing Sanctuary

01 · Understanding the medicine

What is Ketamine?

Ketamine is a dissociative anesthetic used in human. It alters perception, attention, pain, memory, and sense of self. In the United States, the related medicine esketamine (the S-enantiomer) is FDA-approved for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in both cases under a restricted, supervised program and with an oral antidepressant for the latter. The label says it has not been shown to prevent suicide 1. Racemic ketamine infusions for depression are not FDA-approved for that indication and are an off-label clinical practice. Early trials reported rapid but usually brief improvement in some adults; long-term benefit and safety remain uncertain 3. This is education, not personal treatment advice or clinician review.

02 · The science

How it works

Ketamine and esketamine are non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists 1. By changing glutamate signaling and downstream plasticity pathways, ketamine may temporarily alter mood, threat, pain, and perception circuits; its antidepressant mechanism is not settled. Dissociation is not proof of spiritual transformation. Studies mostly enroll adults with diagnosed depression after other treatments and often exclude cardiovascular disease, psychosis, and substance-use risk. Findings cannot be generalized to every diagnosis, age group, culture, or setting 3.

03 · Hope, with context

What researchers are exploring

Potential benefit is not a promised outcome. The study population, support, setting, and evidence quality all matter.

Rapid reduction of depressive symptoms in some treatment-resistant adults

Controlled studies of intravenous racemic ketamine found improvement can begin within about a day, with benefit commonly measured over a short window. Esketamine trials support a role for selected adults with treatment-resistant depression, but response is variable and does not establish a permanent effect 1 3.

Randomized trials and reviews in studied adults; not evidence for unsupervised use.

Source 1 Source 3

A possible option when depression is difficult to treat

Esketamine is an approved option for adults with treatment-resistant depression, while racemic ketamine is investigated or used off-label in some health systems. Evidence is smaller and less settled for bipolar depression, PTSD, OCD, pain, and substance-use disorders 1 3.

Promising but formulation- and condition-specific; outside approved indications is investigational or off-label.

Source 1 Source 3

A research tool for understanding glutamate and mood

Ketamine has helped researchers test fast-acting, glutamatergic approaches to depression and investigate how changes in NMDA signaling may relate to mood and neuroplasticity. This is not itself an individual benefit 2 3.

Mechanistic and clinical research; translation to durable outcomes is incomplete.

Source 2 Source 3

04 · Informed decisions

Safety & medication interactions

Do not start, stop, combine, or taper medicines based on this page. Discuss your complete medication list and health history with your prescriber or pharmacist.

Dissociation, sedation, and impaired judgment

Perceptual changes, detachment, dizziness, nausea, anxiety, confusion, and impaired motor skills can occur. Supervised esketamine requires observation because sedation, dissociation, and respiratory depression may occur 1.

Source 1 Source 2

Cardiovascular and breathing risks

Ketamine/esketamine can raise blood pressure and heart rate; serious vascular conditions are contraindications for esketamine. Respiratory depression is a boxed-warning risk, especially with other sedating substances, and urgent medical care is appropriate for breathing difficulty, chest pain, fainting, or severe agitation 1.

Source 1 Source 2

Psychiatric destabilization and misuse potential

Hallucinations, dysphoria, anxiety, flashbacks, or confusion can occur. Ketamine is reinforcing and can be misused or lead to dependence; evidence about repeated exposure, cognition, and long-term psychiatric effects is limited. Risk may be higher with psychosis, mania, or substance-use disorder 1 2 3.

Source 1 Source 2 Source 3

Urinary, liver, and other longer-term harms

Frequent or heavy nonmedical use has been associated with bladder/urinary problems and cognitive harms. Long-term safety of repeated therapeutic exposure, including in underrepresented populations, remains incompletely characterized 2 3.

Source 2 Source 3

Interaction considerations

Alcohol, opioids, benzodiazepines, sleep medicines, and other central-nervous-system depressants can compound sedation and breathing risk. Medicines or conditions that raise blood pressure, and drugs affecting alertness, may alter risk; the FDA label also notes clinically relevant interaction considerations for central depressants, psychostimulants, and monoamine oxidase inhibitors 1. A prescriber should review medicines, substances, pregnancy, and health history. Do not stop or combine medicines based on this entry.

Explore the Safety Center

05 · The wider story

History, culture & legal context

Ketamine is a modern anesthetic and dissociative drug, not an Indigenous medicine or a traditional ceremonial plant. It is not interchangeable with living Indigenous healing traditions, whose authority and protocols belong to their communities. Clinical ketamine care and cultural or spiritual practice are distinct contexts; respectful education should avoid borrowing ceremony, claiming lineage, or treating dissociation as a universal spiritual experience.

Legal context

In the United States, ketamine is a Schedule III controlled substance 4. Ketamine is FDA-approved as an anesthetic, while esketamine has the specific adult depression indications described above; racemic ketamine for depression is off-label 1 2. Prescribing and supervised-service rules vary and change. Check the current law and regulator guidance where you live; legality is not safety evidence.

06 · Beyond the experience

Preparation & integration

Before

Preparation for any legitimate clinical evaluation includes a qualified medical assessment of diagnosis, goals, cardiovascular and psychiatric history, pregnancy or breastfeeding status, substance-use history, current medicines, transportation, and emergency procedures. Approved esketamine is administered only through its required risk-management program with monitoring; this is not a recommendation to seek treatment. Unsupervised, recreational, or diverted ketamine carries additional uncertainty and danger 1.

After

If a person receives ketamine in a lawful clinical setting, follow-up should be coordinated with the treating team and existing mental-health care. Integration may mean discussing mood, dissociation, memories, functioning, adverse effects, and next-care decisions with a clinician; it does not guarantee insight, symptom remission, or durable change. New suicidal thoughts, mania, psychosis, severe confusion, chest pain, or breathing problems require urgent professional help.

Questions to bring to your care team

Which formulation and indication is being discussed, and is it approved or off-label where I live?
What screening, monitoring, emergency support, follow-up, and continuity of care are provided, including for blood pressure, breathing, psychiatric symptoms, and misuse risk?
How will uncertain or short-lived benefits, alternatives, costs, privacy, and stopping be discussed without promising an outcome?

Preparation guide →Integration support →

07 · Follow the evidence

Sources & further reading

Read the original work. Publication is not endorsement, and a source check is not independent clinical review.